| TNF receptor-associated factor 6 in advanced non-small cell lung cancer: clinical and prognostic implications. | |
| | |
MedLine Citation:
|
PMID: 22736025 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) represents a central point of convergence for the signal transduction by the TNFR and the IL-lR/TLR superfamilies. We conducted this retrospective clinical study focusing on TRAF6 expression associated with overall survival and chemotherapeutical sensitivity in a large population with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 324 patients with stage III and IV NSCLC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the expression of TRAF6, apoptosis-related proteins Bcl-2, Bax, Fas, and FasL, as well as the density of CD8(+) and FOXP3(+) tumor infiltrating lymphocytes (TILs) in tumor microenvironment. RESULTS: A total of 193 carcinomas (59.6 %) were identified as high expression of TRAF6. TRAF6 expression was not significantly related with histology and clinic stage. No obvious correlation of TRAF6 expression with apoptosis-related protein and TILs density was identified. TRAF6 status was correlated inversely with response to chemotherapy in overall patients (response rates 24.9 and 32.8 %, for patients with high-TRAF6 and low-TRAF6 tumors, respectively, P = 0.039). However, multivariate logistic regression analysis could not identify TRAF6 status as an independent predictor for the response to chemotherapy in overall cohort (95 % CI: 0.91-3.32, P = 0.065). The overall survival was not significantly associated with TRAF6 expression (P = 0.616). CONCLUSIONS: Our results provide new insight for the biological properties and clinical relevance of the TRAF6 in NSCLC. TRAF6 is a promise target for therapeutic strategies against cancer. |
| | |
Authors:
|
Hui Liu; Tiantuo Zhang; Jin Ye; Hongtao Li; Jing Huang; Xiaodong Li; Benquan Wu; Xubing Huang; Jinghui Hou |
Related Documents
:
|
16518065 - Immunohistochemical evaluation of hormone receptor status for predicting response to en... 18457865 - Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high... 16894565 - Molecular determinants of irinotecan efficacy. 22806575 - Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic rev... 22292735 - Prognostic value of bcl-2 and bax tumor cell expression in patients with non muscle-inv... 4039625 - Doxorubicin plus cisplatin in the treatment of apudomas. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-6-27 |
Journal Detail:
|
Title: Journal of cancer research and clinical oncology Volume: - ISSN: 1432-1335 ISO Abbreviation: - Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-6-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902060 Medline TA: J Cancer Res Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Pulmonary and Critical Care, Department of Internal Medicine, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe street, Guangzhou, 510630, China, huiliu_sums@yahoo.com.cn. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppressi...
Next Document: HIF-1? induced by ?-elemene protects human osteosarcoma cells from undergoing apoptosis.